Inotuzumab Ozogamicin in B-Cell Non-Hodgkin's Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy

MLA

Andre Goy, et al. “Inotuzumab Ozogamicin in B-Cell Non-Hodgkin’s Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy.” Annals of Oncology, vol. 23, Oct. 2012, p. xi94. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........99720f731b762d4643940ed69345f7e3&authtype=sso&custid=ns315887.

APA

Andre Goy, Steven Y. Hua, M. Egyed, J. Leach, Kiyoshi Ando, Erik Vandendries, Kensei Tobinai, Ted Feldman, Kiyohiko Hatake, Angela Volkert, & Michinori Ogura. (2012). Inotuzumab Ozogamicin in B-Cell Non-Hodgkin’s Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy. Annals of Oncology, 23, xi94.

Chicago

Andre Goy, Steven Y. Hua, M. Egyed, J. Leach, Kiyoshi Ando, Erik Vandendries, Kensei Tobinai, et al. 2012. “Inotuzumab Ozogamicin in B-Cell Non-Hodgkin’s Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy.” Annals of Oncology 23 (October): xi94. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........99720f731b762d4643940ed69345f7e3&authtype=sso&custid=ns315887.